Full Press Release Details
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
June 23, 2026
NXL Positive Sentiment Score: 75/100
No More Side Effects: Nexalin’s Non-Invasive Approach to Treating Depression & PTSD
Key Takeaway: Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This award recognizes research evaluating the company's proprietary DIFS™ platform, which aims to provide a non-invasive treatment for depression and PTSD. The acknowledgment underscores the potential impact of Nexalin's technology in mental health care.
Price reaction · baseline $1.26 (2024-10-18 close) · 2 other NXL headline(s) in the window, move may be shared
day 0 close
+17.5%
day 1
+42.1%
day 3 · peak
+70.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Nexalin's proprietary DIFS™ platform shows promise in treating depression and PTSD.
- The recognition at BRAIN 2026 highlights the significance of their research.
- The non-invasive approach may attract more interest in mental health treatments.
Frequently Asked Questions
What is Nexalin's DIFS™ platform?
Nexalin's DIFS™ platform is a proprietary technology aimed at treating depression and PTSD.
What award did Nexalin's researcher receive?
The researcher received the Young Researcher Award at BRAIN 2026 for their work.
What is the significance of the BRAIN 2026 event?
BRAIN 2026 recognizes innovative research in mental health, highlighting advancements like Nexalin's.
Is Nexalin's treatment invasive?
No, Nexalin's approach is non-invasive, making it a potentially safer option for patients.